Insulet PODD releases its next round of earnings Wednesday. Get the latest predictions in Benzinga's essential guide to the company's Q4 earnings report.
Earnings and Revenue
Insulet's per-share loss will be near 8 cents on sales of $125.15 million, according to Wall Street analysts.
Insulet EPS in the same period a year ago came in at a loss of 16 cents per share. Sales were $103 million. If the company were to match the consensus estimate, earnings would be down 50 percent. Sales would be up 20.83 percent from the year-ago period.
In comparison to analyst estimates in the past, here's how the company's reported EPS stacks up:
Quarter | Q3 2017 | Q2 2017 | Q1 2017 | Q4 2016 |
EPS Estimate | -0.1 | -0.13 | -0.16 | -0.05 |
EPS Actual | -0.04 | -0.13 | -0.17 | -0.16 |
Stock Performance
Over the last 52-week period, shares of Insulet are up 76.72 percent. Analysts have adjusted their estimates higher for EPS and revenues over the past 90 days. The average rating by analysts on Insulet stock is a Neutral. The strength of this rating has maintained conviction over the past 90 days.
Conference Call
Insulet is scheduled to hold a conference call at 4:30 p.m. ET and it can be accessed here.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.